Insider Trading Alert - CIEN, JAZZ And WDFC Traded By Insiders

Stocks with insider trader activity include CIEN, JAZZ and WDFC
By TheStreet Wire ,

Yesterday, Nov. 17, 2015, 80 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $220.10 to $2,203,162.50.

Highlighted Stocks Traded by Insiders:

Ciena (CIEN) - FREE Research Report

Alexander Stephen B, who is Sr VP Chief Technology Officer at Ciena, sold 3,500 shares at $23.64 on Nov. 17, 2015. Following this transaction, the Sr VP Chief Technology Officer owned 126,131 shares meaning that the stake was reduced by 2.7% with the 3,500-share transaction.

Rothenstein David M, who is Sr. VP, General Counsel at Ciena, sold 1,500 shares at $23.64 on Nov. 17, 2015. Following this transaction, the Sr. VP, General Counsel owned 241,409 shares meaning that the stake was reduced by 0.62% with the 1,500-share transaction.

The shares most recently traded at $24.03, up $0.39, or 1.62% since the insider transaction. Historical insider transactions for Ciena go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 2,400
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 62,069
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 141,516

The average volume for Ciena has been 2.9 million shares per day over the past 30 days. Ciena has a market cap of $3.3 billion and is part of the technology sector and telecommunications industry. Shares are up 24.32% year-to-date as of the close of trading on Tuesday.

Ciena Corporation provides equipment, software, and services that support the transport, switching, aggregation, service delivery, and management of voice, video, and data traffic on communications networks worldwide. Currently, there are 13 analysts who rate Ciena a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CIEN - FREE

TheStreet Quant Ratings

rates Ciena as a

hold

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full

Ciena Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Miller Michael Patrick, who is SVP, US Commercial at Jazz Pharmaceuticals, sold 100 shares at $134.03 on Nov. 17, 2015. Following this transaction, the SVP, US Commercial owned 13,690 shares meaning that the stake was reduced by 0.73% with the 100-share transaction.

McGill Iain, who is SVP, Europe & Rest of World at Jazz Pharmaceuticals, sold 2,821 shares at $135.67 on Nov. 17, 2015. Following this transaction, the SVP, Europe & Rest of World owned 19,146 shares meaning that the stake was reduced by 12.84% with the 2,821-share transaction.

The shares most recently traded at $142.69, up $7.02, or 4.92% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 4,500
  • 12-Week # shares sold: 10,125
  • 24-Week # shares sold: 28,600

The average volume for Jazz Pharmaceuticals has been 762,900 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $8.4 billion and is part of the health care sector and drugs industry. Shares are down 16.09% year-to-date as of the close of trading on Tuesday.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a P/E ratio of 26.3. Currently, there are 10 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings

rates Jazz Pharmaceuticals as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, good cash flow from operations, expanding profit margins and impressive record of earnings per share growth. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Jazz Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

WD-40 (WDFC) - FREE Research Report

Freeman Michael L, who is Division President, Americas at WD-40, sold 3,709 shares at $94.86 on Nov. 17, 2015. Following this transaction, the Division President, Americas owned 27,286 shares meaning that the stake was reduced by 11.97% with the 3,709-share transaction.

The shares most recently traded at $96.79, up $1.93, or 1.99% since the insider transaction. Historical insider transactions for WD-40 go as follows:

  • 4-Week # shares sold: 2,004
  • 12-Week # shares sold: 2,004
  • 24-Week # shares bought: 52
  • 24-Week # shares sold: 2,004

The average volume for WD-40 has been 72,000 shares per day over the past 30 days. WD-40 has a market cap of $1.4 billion and is part of the basic materials sector and chemicals industry. Shares are up 13.31% year-to-date as of the close of trading on Monday.

WD-40 Company develops and sells maintenance products, and homecare and cleaning products. The stock currently has a dividend yield of 1.6%. The company has a P/E ratio of 31.3. Currently, there are no analysts who rate WD-40 a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WDFC - FREE

TheStreet Quant Ratings

rates WD-40 as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, growth in earnings per share and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

WD-40 Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Loading ...